by dyadic | Jan 11, 2021 | Press Releases
JUPITER, FL / ACCESSWIRE / January 11, 2021 / Dyadic International, Inc. (“Dyadic”) (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower...
by dyadic | Dec 9, 2020 | Press Releases
JUPITER, FL / ACCESSWIRE / December 9, 2020 / Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to...
by dyadic | Nov 12, 2020 | Press Releases
Six new and expanded animal and human health collaborations since Q2 2020 Expanded presence in the Asia Pacific Region Important progress and expanded animal efficacy data in COVID-19 vaccine and antibody programs ZAPI to conduct additional animal studies for...
by dyadic | Oct 29, 2020 | Press Releases
JUPITER, FL / ACCESSWIRE / October 29, 2020 / Dyadic International, Inc. (“Dyadic”) (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development, lower production...
by dyadic | Oct 12, 2020 | Press Releases
C1 Expression of SARS-CoV-2 Monoclonal Antibody Achieved Ten On-going Animal Trials of C1 Expressed SARS-CoV-2 Receptor Binding Domain (RBD) Antigen by Seven Different Collaborators Record Expression Level of C1 SARS-CoV-2 RBD Antigen (3 g/l in 5 days) Non-Exclusive...
